Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies...

Full description

Bibliographic Details
Main Authors:	Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Cells
Subjects:	immunogenic therapy immune checkpoint inhibitors combined therapies cancer T cells stem-cell like memory T cells
Online Access:	https://www.mdpi.com/2073-4409/9/7/1727

Similar Items

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
by: Thaiz Rivera Vargas, et al.
Published: (2019-05-01)

Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
by: Jingjing Deng, et al.
Published: (2022-03-01)

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
by: Mie Linder Hübbe, et al.
Published: (2020-09-01)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
by: Somayeh Vafaei, et al.
Published: (2022-01-01)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
by: Qi J, et al.
Published: (2021-02-01)

Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
by: Siwei Yang, et al.
Published: (2024-04-01)

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
by: Wendy W. L. Lee, et al.
Published: (2024-04-01)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
by: Qinghua Wu, et al.
Published: (2022-07-01)

Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer
by: Hanfei GUO, et al.
Published: (2020-02-01)

Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
by: Xiangyu Chen, et al.
Published: (2024-02-01)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
by: Jing Zhao, et al.
Published: (2019-10-01)

Research progress of immune checkpoint inhibitors in ovarian cancer
by: Lingli Zhao, et al.
Published: (2024-12-01)

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
by: Hui Dong, et al.
Published: (2023-01-01)

Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment
by: Yang Hao, et al.
Published: (2022-08-01)

Overcoming Resistance to Immune Checkpoint Inhibitor Therapy Using Calreticulin-Inducing Nanoparticle
by: Sri Vidhya Chandrasekar, et al.
Published: (2023-06-01)

Current state of immune checkpoints therapy for glioblastoma
by: He Wang, et al.
Published: (2024-01-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
by: Faezeh Sharafi, et al.
Published: (2022-08-01)

Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle
by: Caecilia Sukowati, et al.
Published: (2022-09-01)

Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
by: Christopher J. LaRocca, et al.
Published: (2018-11-01)

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
by: Ming-Yan Shi, et al.
Published: (2023-01-01)

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Li Tao, et al.
Published: (2021-10-01)

Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma
by: CAO Jiali, et al.
Published: (2023-05-01)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
by: Dylan J. Martini, et al.
Published: (2022-08-01)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
by: Qingqing Xie, et al.
Published: (2022-09-01)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
by: Yujie Zhao, et al.
Published: (2022-09-01)

Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy
by: Xinlun Dai, et al.
Published: (2022-05-01)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
by: Jun Gong, et al.
Published: (2018-10-01)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
by: Zihui Li, et al.
Published: (2020-11-01)

Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor
by: Xinlun Dai, et al.
Published: (2023-12-01)

Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors
by: Yaqian Tan, et al.
Published: (2024-01-01)

Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer
by: Yibo Shi, et al.
Published: (2025-04-01)

Tumor lysis with LTX-401 creates anticancer immunity
by: Wei Xie, et al.
Published: (2019-07-01)

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
by: Li‐Yue Sun, et al.
Published: (2021-10-01)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
by: Xiaohua Li, et al.
Published: (2021-07-01)

Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance
by: Hassan Abushukair, et al.
Published: (2022-01-01)

Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study
by: Dominik A. Barth, et al.
Published: (2022-04-01)

Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
by: Subhamay Adhikary, et al.
Published: (2024-01-01)

New insights into the role of mast cells as a therapeutic target in cancer through the blockade of immune checkpoint inhibitors
by: Domenico Ribatti
Published: (2024-02-01)